alexa Relevance of the T cell Receptor-Ligand Avidity for Immunity to Infection | OMICS International
ISSN: 1948-5948
Journal of Microbial & Biochemical Technology

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Relevance of the T cell Receptor-Ligand Avidity for Immunity to Infection

Magdalena Nauerth1, Kristof Wing1,2, Heinrich Korner2 and Dirk Busch1,3,4*

1Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany

2Menzies Institute for Medical Research, Medical Science Precinct, Hobart, Tasmania, Australia

3DZIF - National Centre for Infection Research, Munich, Germany

4Focus Group “Clinical Cell Processing and Purification”, Institute for Advanced Study, Technische Universität München, Munich, Germany

*Corresponding Author:
Dirk Busch
Institute for Medical Microbiology
Immunology and Hygiene
Technische Universität München
Munich, Germany
Tel: +49 89 28901
E-mail: [email protected]

Received Date: February 29, 2016 Accepted Date: March 24, 2016 Published Date: March 31, 2016

Citation: Nauerth M, Wing K, Korner H, Busch D (2016) Relevance of the T cell Receptor-Ligand Avidity for Immunity to Infection. J Microb Biochem Technol 8:131-135. doi: 10.4172/1948-5948.1000275

Copyright: © 2016 Nauerth M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Microbial & Biochemical Technology

Abstract

Cytotoxic lymphocytes are critical for fighting viral and certain bacterial infections. Therefore, assessing the quality of cytotoxic T cell responses might have important clinical implications. TCR-pMHC binding (avidity) is a key determinant of T cell quality. Here we review currently available technologies for the measurement of TCR-pMHC avidity and their potential relevance for translational applications.

Keywords

T cell; Mycobacterium tuberculosis; Cytomegalovirus; Immunotherapies

Introduction

Chronic infections with viruses and intracellular bacteria remain a leading cause of morbidity and mortality worldwide. The Human Immunodeficiency Viruses (HIV) account for over 4% of the Years of Life Lost globally [1], continue to be largely incurable, and have increasing rates of therapeutic resistance [2]. Mycobacterium tuberculosis is estimated to latently infect between two and three billion people worldwide [3], with mortality in active, extensively drug resistant (XDR-TB) cases approaching 50% in spite of rigorous treatment [4]. Similarly, cytomegalovirus (CMV) and Epstein-Barr virus (EBV) cause significant morbidity and morality in immunosuppressed patients, and are regularly refractory to current therapies [5]. The treatment of each of these conditions is associated with, at times, severe toxicities that limit management and prevent curative treatment [6-8]. These inadequacies have led to the investigation of novel immunotherapies, including vaccination and adoptive cell therapy (ACT).

The control and clearance of intracellular pathogens usually requires robust cytolytic immunity, pivotally mediated by antigenspecific CD8+ T cells [9]. Highly diverse repertoires of CD8+ T cells in the pool of lymphocytes, with each cell expressing a unique T cell receptor (TCR) on its surface, are provided by thymic development and selection. These TCRs bind, together with the CD8 co-receptor, to major histocompatibility complex I molecules loaded with cognate peptides (pMHC), which are expressed on the surface of target cells. Infected cells presenting peptides from the intracellular pathogen can thereby be specifically recognised by T cells, and are killed or modulated due to the consequent effector functions of the T cell. In this context, the term 'T cell avidity' describes the efficiency of these effector functions after antigen encounter and is principally affected by the binding strength between the TCR, its cognate pMHC ligand, and associated co-receptors, the so called 'structural avidity'. The structural avidity of TCR-pMHC binding can be expressed by the equilibrium constant KD, a ratio between the association (kon) rate and the dissociation (koff) rate [10,11] with low equilibrium constants indicative of high avidity TCR-pMHC complexes. Interactions characterised by high structural avidities are correlated with increased T cell functional avidities [10,12], with a major determinant of the structural TCR avidity being the koff –rate [10,13]. There is growing interest in identifying T cells with high avidity TCRs, as they have been shown to possess superior efficacy towards target cells in vivo and in vitro [14-16]. Given that high avidity T cells recognize targets earlier and mediate superior effector functions [14], their generation and precise detection becomes an important aspect for the development of more effective anti-infective immunotherapies.

Measuring TCR-pMHC Interaction

Functional assays, such as interferon-γ synthesis, interleukin-2 release or in vitro cell-mediated lysis, can be strongly affected by the expression level of TCRs and co-receptors, and alterations in the signaling cascade [17], and are cumbersome to undertake. Several different methods have been developed, which aim to assess the structural avidity of TCR-pMHC binding in order to overcome the limitations of functional assays, as proxies for functionality. Surface Plasmon Resonance (SPR) (Figure 1a), initially developed by Liedberg et al. [18], has been adapted to assess the binding of TCRs or MHCs devoid of co-receptors, with one member of the pair being soluble and one substrate-bound, by detecting changes in the mass of the bound complexes. Typically, this technique is complicated by the technically challenging and labour intensive production of high-purity soluble TCRs and MHC molecules. Furthermore, the contribution of the CD8 co-receptor and other potentially involved surface molecules to binding is unable to be interrogated, thus preventing assessment of the physiological conditions present at the T cell surface.

microbial-biochemical-technology-methodologies-quantification-avidity

Figure 1: Methodologies for the quantification of TCR Avidity

Conversely, assays based on multimer binding (Figure 1b) and dissociation (Figure 1c) attempt to measure the structural avidity of TCR-pMHC binding on the surface of living T cells [13,19]. These assays monitor the dissociation of multimeric complexes, can thus have half-lives of dissociation in the range of hours to days, are strongly influenced by the quality of multimer reagents, as well as the concentration and affinity of MHC-blocking antibodies used, a pre-requisite for the assay as it permits dissociation of the multimeric complex [20]. These factors result in significant inter-assay and inter-investigator variability, negatively effecting the reliability of this assay.

In an effort to overcome these inadequacies, Huang et al. [21] and Huppa et al. [22] have developed two-dimensional TCR-pMHC binding assays to better approximate the physiological situation, where both binding partners are embedded in ‘two-dimensional’ membranes. These assays provide valuable insights into TCR-pMHC physiology, but have thus far been unable to lend themselves to high-throughput translational applications.

Determining T cell Avidity: The TCR-Ligand koff –Rate Assay

To enable the rapid and accurate measurement of truly monomeric TCR-pMHC interactions on living T cells, we developed the TCR-Ligand koff –rate assay (Figure 2) based on reversible MHC multimers, so-called MHC StrepTamers [23]. Fluorescently-labelled MHC-I molecules, which associate with their cognate TCRs are multimerized onto StrepTactin molecules via C-terminal StrepTag sequences, permitting the stable identification of living CD8+ T cells via cooperative binding (Figure 2a). In the presence of D-biotin, the StrepTag is very rapidly displaced from the StrepTactin molecule, causing disintegration of the multimer complex, whilst leaving monomeric MHC-I molecules bound to their cognate TCRs (Figure 2b). Dissociation of these MHC molecules from the surface of the T cell is visible as a decay in fluorescent intensity over time, readily permitting the assessment of the koff –rate (Figure 2c) [24].

microbial-biochemical-technology-assay-antigen-binding

Figure 2: koff-rate assay

We analysed human T cells specific for CMV from healthy donors’ PBMCs via the fluorescence microscopy koff –rate assay, and demonstrated high reproducibility between experiments, dissociations, and even unknown identical clones [24]. Correlation of the koff –rate and ex vivo cytokine and cytolytic assays demonstrated a clear association between the koff –rate and functionality. Specifically, we have not yet found any endogenous epitope-specific T cell which exhibits fast koff –rates and still high functionality [17], a constellation that could be achieved by a predominantly fast kon–rate. For CMV-specific CD8+ T cells, differences in koff –rate again correlated with the functional competence of the respective populations. Furthermore, we have demonstrated a clear correlation between protectivity and the koff –rate of T cells used in adoptive T cell transfer, in preclinical murine models of Listeria moncytogenes and murine CMV infection. In the meantime, others have also developed TCR-pMHC koff –rate assays based on the same principles as our Streptamer based assay [25]. Their methodologies have found a clear correlation between the TCR-pMHC koff –rate and the functionality of the analysed cells [26], supporting our previous findings.

Altogether, our data and the published work of other groups indicates that the koff –rate is an important parameter for the identification and selection of highly functional T cells for different therapeutic and diagnostic applications [17,27].

Applications of the TCR-Ligand koff –Rate Assay

Adoptive T cell transfer experiments in preclinical mouse models have clearly demonstrated the superior protective capacity of T cells with long TCR-pMHC dissociation half-lives and thus low koff –rates [24]. In addition, Stemberger et al. [28] found that the transfer of very high-quality antigen-specific T cells, which is additionally determined by the subset differentiation, can provide exceptionally robust protection against pathogens even at very low cell numbers. Together, these data suggest that the application of the TCR-pMHC koff –rate assay for the identification of highly functional T cell populations could lead to a reduction of the number of T cells needed for the adoptive transfer, reducing costs and possible side effects.

Clinical relevance

The selection of T cell receptors most suitable for genetic engineering of autologous T cell populations could be guided by the koff –rate assay, a technology which has the capacity to broaden the applicability of adoptive T cell therapy. Putatively, individual high-avidity T cells could be identified in a high-throughput manner via the koff –rate assay, with TCR extraction and subsequent recombinant TCR expression [24,29,30]. This process has the capacity to permit the identification of ideal, high-avidity, pathogen-specific TCRs, with opportunities for the characterisation of TCRs bearing the greatest clinical relevance, and the development of novel cellular therapeutics. In patients who have successfully cleared or controlled infections, the koff–rate assay has the potential to identify highly protective populations that have undergone clonal selection and evolution, enabling the directed extraction of TCRs for investigation and clinical application. Several investigators have demonstrated that the transfer of TCRs, in addition to the transfer of antigen specificity [31,32], endows the recipient cells with functional avidities comparable to that of the original population [30,33]. Thus, the development of novel, koff –rate-identified cellular therapeutics for infectious diseases is a tangible application of this technology to the clinical setting.

For example, Appay et al. [9] identify that CD8+-specific responses are crucial in the immune control of HIV, and that high avidity T cells result in superior control of viral replication by exerting a greater selective pressure on variable viruses, which as a result exhibit reduced replicative fitness, elegantly demonstrated in the work of Varela-Rohena et al. [34] Similarly, Sud et al. [35] identify the importance of cytotoxic T cells in controlling infections of M. tuberculosis, in cooperation with other members of the adaptive immune system. Aside from the application of the koff –rate assay to adoptive cell therapies, the assay has the potential to be of great advantage in diagnostic settings. Conceivably, the koff –rate of antigen-specific T cell populations could demonstrate the quality of existing immunity and permit a degree of prognostication about response to illness to occur. Indeed, the work of Hadrup et al. [36] and Wikby et al. [37] have identified several features of an individual’s immune system that are predictive of premature mortality in the aged. Given the short timeframe in which a koff –rate assay can be performed, and the lack of unique equipment required to perform the assay, it would be easily integrated into the clinical environment. Furthermore, the quality of induced CD8+ T cell immune responses after vaccination are of critical importance and are able to be analysed with this assay. Identifying so-called non-responders early in vaccine development and monitoring cohort responses throughout the developmental course of new vaccines are two key applications of this assay. In the context of HIV, it has been shown that the variability of existing assays and the resultant inability to confidently correlate structural TCR-pMHC data with functional data has hampered the development of effective vaccines [9]. Additionally, Parida et al. [4] exemplify the importance of the development of both prophylactic and therapeutic vaccines for M. tuberculosis, as they lament that even with the availability and use of new anti-tuberculous medications, M. tuberculosis will continue to develop therapeutic resistance. Foreseeably, the koff –rate assay could overcome practical difficulties by permitting the inference of functionality from structural avidity with regard to vaccine-induced T cell responses in both the pre-clinical and clinical phases of vaccine design and testing.

Relevance to research

The applications of the koff –rate assay in basic research and clinics are manifold. Comparing koff –rates of T cell populations after primary and secondary infection with Listeria monocytogenes, we found an unexpectedly large variance in the koff–rates of T cells induced after primary infection, with a clear focussing to higher koff –rates for some epitope specificies after secondary infection (unpublished data). This observation is in line with previous findings that narrowing of the repertoire towards higher avidity T cells [38] is largely due to failed recruitment of T cells with low structural avidity into secondary response [39].

The koff –rate assay has also permitted the detailed investigation of chronic immune responses, further demonstrating its application to basic infection research. Infections in which sterilising immunity isn’t achieved, including the pathogens HIV, CMV, EBV, and M. tuberculosis, are characterised by several mechanisms to control pathogen replication, including memory inflation [40]. A well studied example is the course of CMV infection during ageing [36,37], the studies of which have lead to the theory of ‘The Clonal Changing of the Guard’ [41]. According to this theory, high avidity T cells become exhausted and eventually deleted during ongoing infection. Due to reduced thymic output of novel, potentially high-avidity T cells, they are gradually replaced by sub-dominant clones [42], each of which has a lower affinity for MHC-presented viral antigens. This requires larger populations to prevent fulminant viral infection, such that global functional avidity is maintained, and so gradually occupy a larger proportion of the peripheral T cell pool. Pertinently, in a mouse model of chronic murine CMV infection and in accordance with this theory, we found a clear tendency towards inflating populations with decreasing koff –rate during chronic infection (unpublished data). Further investigation of immune phenomena using the koff –rate assay will indubitably yield new insights into the physiology of the adaptive immune system.

In summary, the TCR-pMHC koff –rate assay allows for the accurate determination of the TCR-ligand avidity of cytotoxic T cells. This can be used for the identification and isolation of highly functional T cells to improve adoptive T cell therapy of severe infections, to monitor the quality of existing and induced immunity, and to gain insights into the course of infections in basic research.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 8331
  • [From(publication date):
    April-2016 - May 26, 2018]
  • Breakdown by view type
  • HTML page views : 8265
  • PDF downloads : 66
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7